Gallen Consensus in 2013, it was agreed that the breast cancer molecular subtypes with therapeutic importance would be luminal A, luminal B, luminal HER2, pure HER2, and triple-negative (homologous to basal-like).3 Here, ERBB2 is linked to breast cancer.